MST1R and prostate carcinoma: Myeloid-specific RON loss showed reduced prostate cancer cell growth, reduced STAT3 activation, downregulated Arginase-1 expression (a marker of pro-tumorigenic macrophage polarization), and upregulation of iNOS (a marker of anti-tumorigenic macrophage polarization).